MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ
8.44
+0.12
+1.44%
After Hours: 8.42 -0.02 -0.22% 18:44 03/21 EDT
OPEN
8.26
PREV CLOSE
8.32
HIGH
8.53
LOW
8.23
VOLUME
2.06M
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.710
MARKET CAP
1.16B
P/E (TTM)
214.76
1D
5D
1M
3M
1Y
5Y
1D
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
NASDAQ · 3d ago
Weekly Report: what happened at AUPH last week (0310-0314)?
Weekly Report · 6d ago
Weekly Report: what happened at AUPH last week (0303-0307)?
Weekly Report · 03/10 10:33
Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia
TipRanks · 03/08 13:04
Aurinia Pharmaceuticals CMO Makes Significant Stock Sale
TipRanks · 03/08 02:13
Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors
Barron‘s · 03/07 21:47
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options
NASDAQ · 03/07 19:06
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Barchart · 03/07 01:32
More
About AUPH
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

Webull offers Aurinia Pharmaceuticals Inc stock information, including NASDAQ: AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.